If Dendreon made it fr 5 to 25 in a few weeks, PRIOR to FDA approval and while having many more shares than CLDX outstanding...there is no reason CLDX can't move much higher and faster.
Again, all prior to approval...
After approval and with CLDX's pipeline...all bests are off.
I agree. Celldex has an outstanding pipeline. Also, each of Celldex's drug prospects have multiple indications. On top of that, I believe some of their compounds can used together in a synergistic way.